Contineum's MOONLIGHT-1 Phase 2 trial fails primary endpoint in MDD

Contineum Therapeutics, Inc.

MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 in MDD did not meet primary efficacy endpoint.
Primary endpoint: MADRS total score change at Day 5 vs placebo; no new safety signals.
JNJ-5120/PIPE-307 developed by J&J under global license; J&J evaluating exploratory endpoints.
Randomized, double-blind, placebo-controlled proof-of-concept trial in adult MDD (NCT06785012).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.